The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
MEDIPOST Secures Exclusive Commercialization Agreement with Teikoku Seiyaku for CARTISTEM® in Japan
Dec 19, 2025•6 months ago
Contract Type
agreement
South KoreaBiotechnologyHealth Care
Description
MEDIPOST has entered a multi-year partnership with Teikoku Seiyaku for the commercialization of CARTISTEM® in Japan. This agreement involves an upfront payment of $8 million to MEDIPOST, enabling a joint effort to promote and distribute the treatment for knee osteoarthritis.
Company Information
Company
MEDIPOST Ltd
Location
South Korea
About
MEDIPOST Co., Ltd. is a fully integrated cell therapy biotechnology company. They specialize in developing innovative treatments for various medical conditions, particularly focusing on cell therapies. Their product CARTISTEM® targets knee osteoarthritis using advanced stem cell technology.
Predictive Intelligence
Strategic
ML-powered predictions for MEDIPOST Ltd's next move
South KoreaBiotechnologyHealth Care